GlycoMimetics, Inc.
03/17/2016
PDF
Add to Briefcase

GlycoMimetics to Present New Preclinical Data on Its E-selectin-CXCR4 Dual Antagonist at AACR Annual Meeting 2016

Data bolsters scientific rationale for clinical evaluation of GMI-1359 in AML patients harboring aberrant FLT3 and in patients with pancreatic cancer

GAITHERSBURG, Md.--(BUSINESS WIRE)-- GlycoMimetics, Inc. (NASDAQ:GLYC) announced today that pre-clinical research demonstrating the potential of its third drug candidate, GMI-1359, will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2016 in New Orleans. An oral presentation and a poster will highlight data on GMI-1359, a potent dual antagonist of both E-selectin and CXCR4, demonstrating anti-tumor activity in preclinical models of pancreatic cancer and acute myeloid leukemia (AML), respectively. In a pancreatic cancer model, GMI-1359 showed significant disruption of the tumor microenvironment and inhibited tumor metastasis. In an AML model, while either GMI-1359 or sorafenib alone reduced tumor burden, antitumor activity was significantly enhanced when GMI-1359 was given in combination with sorafenib, over either treatment alone. The AACR Annual Meeting 2016 takes place from April 16 to 20, 2016, at the Ernest N. Morial Convention Center.

"Our data provides additional preclinical support for initiating clinical trials of GMI-1359 in both FLT3 mutated AML and pancreatic cancer. GMI-1359's ability to disrupt the tumor microenvironment and known pathways of cancer cell trafficking has great potential to improve survival in some of the most challenging cancers," said John Magnani, Ph.D., GlycoMimetics Vice President and Chief Scientific Officer. "We are completing the IND-enabling program for this promising agent and plan to file an IND later this year."

The AACR presentations from GlycoMimetics, including abstract title, session times, and locations, include the following:

About GlycoMimetics, Inc.

GlycoMimetics is a Phase 3 clinical-stage biotechnology company developing its proprietary drug candidate, rivipansel, a pan-selectin antagonist, for the treatment of vaso-occlusive crisis in sickle cell disease, through its strategic partner, Pfizer. GlycoMimetics's wholly-owned lead drug candidate, GMI-1271, an E-selectin antagonist, is being evaluated for AML and other blood disorders, for which differentiating initial data from an ongoing Phase 1/2 study have been announced. A third candidate, GMI-1359, a combined CXCR4 and E-selectin antagonist, is being readied for the clinic in 2016. Fueling the pipeline, an in-house discovery and research group is focused on novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. Learn more at www.glycomimetics.com.

Investor:
Shari Annes, 650-888-0902
sannes@annesassociates.com
or
Media:
Jamie Lacey-Moreira, 410-299-3310
jamielacey@presscommpr.com

Source: GlycoMimetics

News Provided by Acquire Media